TY - JOUR
T1 - Leishmaniasis Vaccines
T2 - Applications of RNA Technology and Targeted Clinical Trial Designs
AU - Duthie, Malcolm S
AU - Machado, Bruna A S
AU - Badaró, Roberto
AU - Kaye, Paul M
AU - Reed, Steven G
N1 - © 2022 by the authors
PY - 2022/10/29
Y1 - 2022/10/29
N2 - Leishmania parasites cause a variety of discrete clinical diseases that present in regions where their specific sand fly vectors sustain transmission. Clinical and laboratory research indicate the potential of immunization to prevent leishmaniasis and a wide array of vaccine candidates have been proposed. Unfortunately, multiple factors have precluded advancement of more than a few Leishmania targeting vaccines to clinical trial. The recent maturation of RNA vaccines into licensed products in the context of COVID-19 indicates the likelihood of broader use of the technology. Herein, we discuss the potential benefits provided by RNA technology as an approach to address the bottlenecks encountered for Leishmania vaccines. Further, we outline a variety of strategies that could be used to more efficiently evaluate Leishmania vaccine efficacy, including controlled human infection models and initial use in a therapeutic setting, that could prioritize candidates before evaluation in larger, longer and more complicated field trials.
AB - Leishmania parasites cause a variety of discrete clinical diseases that present in regions where their specific sand fly vectors sustain transmission. Clinical and laboratory research indicate the potential of immunization to prevent leishmaniasis and a wide array of vaccine candidates have been proposed. Unfortunately, multiple factors have precluded advancement of more than a few Leishmania targeting vaccines to clinical trial. The recent maturation of RNA vaccines into licensed products in the context of COVID-19 indicates the likelihood of broader use of the technology. Herein, we discuss the potential benefits provided by RNA technology as an approach to address the bottlenecks encountered for Leishmania vaccines. Further, we outline a variety of strategies that could be used to more efficiently evaluate Leishmania vaccine efficacy, including controlled human infection models and initial use in a therapeutic setting, that could prioritize candidates before evaluation in larger, longer and more complicated field trials.
U2 - 10.3390/pathogens11111259
DO - 10.3390/pathogens11111259
M3 - Review article
C2 - 36365010
SN - 2076-0817
VL - 11
JO - Pathogens (Basel, Switzerland)
JF - Pathogens (Basel, Switzerland)
IS - 11
M1 - 1259
ER -